Nihon Kohden Corporation
6849.TMEDIUMScore: 42.2Core · Weight: 8%· Data as of 2026-05-25
Investment Thesis
Mean-reversion thesis: SLOWER than expected. FY2026: revenue +4.3% to ¥235.1B, but operating income FELL 9.5% to ¥18.7B (OpMar 7.97%, below target). Ordinary profit +10.7% to ¥22.5B on non-operating income. Q4 FY2026 operating profit ¥10.6B (+55.3% YoY) — strong exit momentum. FY2027 guidance: operating profit +25.4% to ¥23.5B (implied OpMar ~10%) — recovery underway. BEACON 2030 15% target unachievable by FY2027 (realistic: 10-12% by FY2027). US expansion: Life Scope G7 monitor launched + Software Central Station FDA-cleared (June 2025). Stock at 52-week low of ¥1,408 on May 15 (just 10 days ago), bounced to ¥1,720 on FY2027 guidance.
Risk
1) BEACON 2030 Phase II target of 15% OpMar by FY2027 now clearly unachievable — sets up credibility risk if FY2028+ targets also missed. 2) PE re-rated from 13.9x to 20.3x without EPS growth — thesis requires FY2027 margin recovery to justify valuation. 3) Domestic revenue slightly declined despite aging tailwinds — competitive or procurement timing risk. 4) R&D and wage inflation headwinds persisting (cited in FY2026 miss).
Monitoring Trigger
If FY2027 Q1 (Oct 2026) OpMar exceeds 9.5%, ADD to 10% (recovery confirmed). If FY2027 full-year OpMar reaches 10%+, re-rate to HIGH conviction. If OpMar stays below 8% for FY2027 H1, TRIM to 5% (structural margin floor, not trough). Watch US revenue contribution — needs to reach 20%+ to diversify domestic risk.
Key Dates
Key Metrics
Supply Chain Evidence
| Evidence | Customer | Product | Detail |
|---|---|---|---|
| confirmed | Japanese hospitals and clinics (nationwide) | Patient monitoring systems, ECG, defibrillators | Duopoly with Fukuda Denshi (6960.T). Japan patient monitoring market ¥400B growing at 7.3% CAGR to 2033. Domestic revenue slightly declined in FY2026 despite aging tailwinds. |
| confirmed | North American ICU facilities (US expansion) | Life Scope G7 patient monitor + Software Central Station (FDA 510(k) K242750) | NEW: Life Scope G7 US launch (2026). FDA 510(k) clearance for software-only central monitoring station (June 2025, K242750). BEACON 2030 phase targets 20%+ North America revenue. |
| confirmed | Patient monitoring, ECG, defibrillators | Domestic duopoly with Fukuda Denshi; Philips/GE are global peers in ICU monitoring. |